Therapeutic | Retifanlimab |
Target | PDCD1 |
Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS |
Light Chain | EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (August '23) | Preregistration |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2019 |
INN Year Recommended | 2020 |
Companies Involved | MacroGenics%3BIncyte Corporation%3BZAI Lab |
Conditions Approved | na |
Conditions Active | Gastic cancers%3BOesophageal cancer%3BAnal cancer%3BEndometrial cancer%3BMerkel cell carcinoma%3BSolid tumours%3BColorectal cancer%3BAcute myeloid leukaemia%3BSquamous cell cancer%3BNon-small cell lung cancer%3BGlioblastoma%3BHead and neck cancer%3BLiposarcoma%3BPancreatic cancer%3BPenile cancer%3BSoft tissue sarcoma |
Conditions Discontinued | Haematological malignancies |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]